Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Tramadol vs JALYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission.
Jalyn is a combination of dutasteride, a 5α-reductase inhibitor that inhibits the conversion of testosterone to dihydrotestosterone (DHT), and tamsulosin, an α1-adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck.
Moderate to moderately severe pain (FDA-approved),Chronic pain (off-label),Restless legs syndrome (off-label),Premature ejaculation (off-label),Osteoarthritis pain (off-label)
Treatment of symptomatic benign prostatic hyperplasia (BPH),Reduction in risk of acute urinary retention,Reduction in risk of need for BPH-related surgery
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day. For moderate to severe pain, 50-100 mg IV or IM every 4-6 hours; maximum 600 mg/day.
1 capsule (0.5 mg dutasteride/0.4 mg tamsulosin) orally once daily, 30 minutes after the same meal each day.
Terminal elimination half-life: approximately 6.3 hours (range 5-9 hours) for tramadol; active metabolite M1 has half-life ~7-9 hours. Clinically, dosing interval is typically every 4-6 hours.
Dutasteride: 5 weeks (t½ ∼3-5 weeks) due to high tissue binding and slow elimination; Tamsulosin: 9-13 hours (t½ ∼9-13 h) in healthy subjects, prolonged in elderly (∼14-15 h).
Hepatic via CYP2D6 and CYP3A4 to active metabolite O-desmethyltramadol (M1) and other inactive metabolites; undergoes conjugation.
Dutasteride is extensively metabolized by CYP3A4 and CYP3A5. Tamsulosin is extensively metabolized by CYP3A4 and CYP2D6.
Primarily renal (90%): ~30% as unchanged drug, ~60% as metabolites. Biliary/fecal: ~10%.
Dutasteride: 40% renal, 60% fecal as metabolites; Tamsulosin: 76% renal (9% unchanged), 24% fecal as metabolites.
Approximately 20% bound to plasma proteins (primarily albumin).
Dutasteride: 99.0-99.5% bound to albumin and alpha-1-acid glycoprotein; Tamsulosin: 94-99% bound to alpha-1-acid glycoprotein.
Approximately 2.6-3.0 L/kg (306-350 L for a 70 kg adult), indicating extensive tissue distribution.
Dutasteride: 300-500 L (∼3-4 L/kg); Tamsulosin: 16 L (∼0.2 L/kg). Dutasteride’s large Vd indicates extensive tissue distribution.
Oral: approximately 70-75% (high first-pass metabolism). Rectal: similar to oral. Intramuscular: 100% (relative to IV).
Oral: Dutasteride ∼60% (capsule); Tamsulosin ∼90% (capsule, under fed conditions slightly reduced).
Cr Cl 30-59 m L/min: extend dosing interval to every 12 hours. Cr Cl <30 m L/min: extend interval to every 12 hours and consider max dose 200 mg/day. Hemodialysis: administer dose after dialysis, with same interval adjustments.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Not recommended for severe renal impairment (GFR <30 m L/min) due to lack of data.
Child-Pugh Class A (mild): 50 mg every 12 hours. Child-Pugh Class B (moderate): 50 mg every 12 hours. Child-Pugh Class C (severe): not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment for mild to moderate impairment (Child-Pugh A or B), but use with caution.
Age ≥16 years: same as adult dosing. Age 12-15 years: 50-100 mg orally every 4-6 hours; max 400 mg/day. For children <12 years: not recommended.
Not indicated for use in pediatric patients. Safety and efficacy not established.
Initiate at 25 mg orally every 6 hours as needed; titrate cautiously to 50 mg every 6 hours; max 300 mg/day. Consider creatinine clearance for dose adjustments.
No specific dose adjustment recommended based on age alone. Monitor for orthostatic hypotension, dizziness, and falls risk, especially in elderly patients. Consider underlying renal and hepatic function.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; interactions with drugs affecting CYP450 isoenzymes; risk of serotonin syndrome; risk of seizures; risk of suicide in patients with depression.
None.
Respiratory depression; seizures; serotonin syndrome; suicide risk; adrenal insufficiency; severe hypotension; use in renal/hepatic impairment; anaphylaxis; use with MAOIs; use in pregnancy (neonatal withdrawal); use in breastfeeding.
Use with caution in combination with other alpha-blockers due to risk of hypotension,Postural hypotension may occur, especially at initiation of therapy,Not recommended for use in women, children, or adolescents due to teratogenic risk,Evaluate for prostate cancer before initiating therapy,Dutasteride may increase risk of high-grade prostate cancer in some studies,Hepatic impairment may alter metabolism of dutasteride
Hypersensitivity; concomitant use of MAOIs or within 14 days; significant respiratory depression; acute or severe bronchial asthma; gastrointestinal obstruction; use in children <12 years for post-tonsillectomy/adenoidectomy pain.
Hypersensitivity to dutasteride, tamsulosin, or any component of the formulation,Use in women of childbearing potential,Use in pediatric patients
No significant food interactions. Grapefruit juice does not substantially affect tramadol metabolism. Avoid alcohol entirely due to additive CNS depression and increased risk of hepatotoxicity. St. John's Wort may reduce tramadol efficacy by inducing CYP3A4 and CYP2D6. High-fat meals may delay absorption but do not significantly affect overall exposure; take extended-release tablets consistently with or without food.
Avoid grapefruit juice; may increase tamsulosin exposure and adverse effects. Administer with a meal (same meal consistency daily) to reduce tamsulosin-related adverse events. No other food interactions known.
First trimester: Limited human data; animal studies show no clear teratogenicity at therapeutic doses but increased risk of neural tube defects at high doses. Second and third trimesters: Risk of neonatal respiratory depression, withdrawal syndrome, and reduced fetal growth with chronic use. Avoid or use lowest effective dose.
JALYN (dutasteride/tamsulosin) is contraindicated in pregnancy. Dutasteride is a 5-alpha-reductase inhibitor that can inhibit dihydrotestosterone formation, potentially causing abnormal development of external genitalia in male fetuses. Tamsulosin is an alpha-1 blocker with limited data but potential risks. First trimester: avoid; second and third trimesters: avoid due to theoretical risk.
Tramadol is excreted into breast milk; relative infant dose estimated at 0.1-3.1% of maternal weight-adjusted dose. M/P ratio approximately 1.3. Monitor infant for drowsiness, feeding difficulties, and constipation. Avoid in mothers with CYP2D6 ultra-rapid metabolism due to increased opioid exposure.
JALYN is not indicated for use in women. Dutasteride and tamsulosin are excreted in rat milk but no human data. M/P ratio unknown; avoid breastfeeding due to potential adverse effects in infants.
Increased clearance and volume of distribution in pregnancy may reduce serum levels; consider dose increase by 20-30% if inadequate analgesia. Avoid in third trimester near delivery due to risk of neonatal respiratory depression. Use lowest effective dose for shortest duration.
No dose adjustments are applicable because JALYN is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy are irrelevant as the drug should not be used.
Tramadol is a prodrug requiring CYP2D6 metabolism to its active metabolite M1 for analgesic effect. Poor metabolizers (7-10% of population) may experience reduced efficacy. Caution with serotonergic drugs due to risk of serotonin syndrome. Seizure risk increased in patients with epilepsy, history of seizures, or concomitant use of SSRIs, SNRIs, tricyclic antidepressants, or other drugs that lower seizure threshold. Dose adjustment needed in renal impairment (Cr Cl <30 m L/min: extended interval or avoid) and hepatic cirrhosis (reduce dose or extend interval). Avoid use in patients with severe hepatic impairment. Not recommended for children <12 years, or <18 years for tonsillectomy/adenoidectomy. Maximum single dose: 100 mg; maximum daily dose: 400 mg (300 mg in patients >75 years). Onset of action: 30-60 minutes; peak effect: 2-3 hours; duration: 4-6 hours.
Jalyn is a fixed-dose combination of dutasteride (5α-reductase inhibitor) and tamsulosin (α1-adrenergic antagonist) for symptomatic benign prostatic hyperplasia (BPH). Onset of symptom relief is faster than either agent alone. Tamsulosin component may cause orthostatic hypotension, especially in elderly patients; counsel to rise slowly. Dutasteride reduces serum prostate-specific antigen (PSA) by approximately 50% after 6 months; PSA levels should be interpreted accordingly. Avoid use in women of childbearing potential; dutasteride is teratogenic and can be absorbed through skin contact with capsules.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush or chew extended-release tablets; swallow whole.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, and overdose.,Tramadol may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Do not stop abruptly; withdrawal symptoms (anxiety, sweating, insomnia, pain) may occur. Taper under medical supervision.,Report symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness, twitching, nausea, diarrhea) immediately.,Seek emergency help if you experience slow/shallow breathing, severe drowsiness, or difficulty waking up.,Dispose of unused tramadol properly via drug take-back programs to prevent accidental ingestion or misuse.,Inform your doctor of all medications you take, especially antidepressants, antipsychotics, and pain relievers.,Pregnancy: avoid during labor; prolonged use may cause neonatal withdrawal syndrome. Breastfeeding: not recommended.,Grapefruit juice has not been shown to interact significantly, but avoid excessive intake.
Take Jalyn 30 minutes after the same meal each day to maintain consistent absorption.,Do not crush, chew, or open capsules; swallow whole.,Avoid grapefruit juice, which may increase tamsulosin levels.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Report symptoms like fainting, severe headache, or prolonged painful erection (priapism) immediately.,Do not donate blood during therapy and for 6 months after stopping due to dutasteride transfer risk.,Use reliable contraception if partner is of childbearing potential; dutasteride can cause fetal harm.
"Concomitant use of tramadol and secobarbital increases the risk of severe adverse effects, including profound sedation, respiratory depression, coma, and death. This is due to additive central nervous system depression from both drugs. Patients should be closely monitored for signs of respiratory depression and excessive sedation."
"Coadministration of tramadol, a weak mu-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), with pargyline, a nonselective monoamine oxidase inhibitor (MAOI), poses a significant risk of serotonin syndrome. This potentially life-threatening condition results from excessive serotonergic activity in the central nervous system, manifesting as altered mental status, autonomic instability, and neuromuscular hyperactivity. Additionally, tramadol's metabolism via CYP2D6 to its active metabolite M1, and use with an MAOI may lead to hypertensive crisis due to enhanced noradrenergic effects."
"Lisuride, a dopamine agonist, and tramadol, an opioid analgesic with serotonergic activity, synergistically increase the risk of serotonin syndrome, a potentially life-threatening condition characterized by altered mental status, autonomic instability, and neuromuscular hyperactivity. The combination may also potentiate CNS depression, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Concurrent use should be avoided or undertaken with extreme caution due to the heightened risk of serious adverse outcomes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Tramadol vs JALYN, answered by our medical review team.
Tramadol is a Opioid Agonist that works by Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission.. JALYN is a 5-Alpha Reductase Inhibitor/Alpha-1 Blocker Combination that works by Jalyn is a combination of dutasteride, a 5α-reductase inhibitor that inhibits the conversion of testosterone to dihydrotestosterone (DHT), and tamsulosin, an α1-adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Tramadol and JALYN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Tramadol is: 50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day. For moderate to severe pain, 50-100 mg IV or IM every 4-6 hours; maximum 600 mg/day.. The standard adult dose of JALYN is: 1 capsule (0.5 mg dutasteride/0.4 mg tamsulosin) orally once daily, 30 minutes after the same meal each day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Tramadol and JALYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Tramadol is classified as Category D/X. First trimester: Limited human data; animal studies show no clear teratogenicity at therapeutic doses but increased risk of neural tube defects at high doses. Second and third trim. JALYN is classified as Category C. JALYN (dutasteride/tamsulosin) is contraindicated in pregnancy. Dutasteride is a 5-alpha-reductase inhibitor that can inhibit dihydrotestosterone formation, potentially causing abn. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.